Details of the Drug Combination

General Information of Drug Combination (ID: DC5AF9T)

Drug Combination Name
Saracatinib Cediranib
Indication
Disease Entry Status REF
Neoplasms Phase 1 [1]
Component Drugs Saracatinib   DMBLHGP Cediranib   DMWO5ZR
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Saracatinib
Disease Entry ICD 11 Status REF
Hematologic tumour 2B33.Y Phase 2 [2]
Metastatic colorectal cancer 2B91 Phase 2 [3]
Osteosarcoma 2B51 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [4]
Saracatinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase ABL1 (ABL) TT3PJMV ABL1_HUMAN Modulator [6]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Modulator [6]
------------------------------------------------------------------------------------
Saracatinib Interacts with 7 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 7A1 (CYP7A1) OT8Z5KLD CP7A1_HUMAN Increases Expression [7]
Tyrosine-protein kinase CSK (CSK) OTP03OD0 CSK_HUMAN Decreases Activity [7]
Neural cell adhesion molecule L1 (L1CAM) OTNWAQ4Y L1CAM_HUMAN Decreases Phosphorylation [8]
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1) OTYRXD2T PMYT1_HUMAN Decreases Activity [9]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Oxidation [10]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Oxidation [10]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Oxidation [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DOT(s)
Indication(s) of Cediranib
Disease Entry ICD 11 Status REF
Peritoneal cavity cancer 2C51.Z Phase 3 [5]
Cediranib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [11]
------------------------------------------------------------------------------------
Cediranib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00475956) Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
3 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
4 Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. Viruses. 2018 May 24;10(6). pii: E283.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5664).
6 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
7 A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol. 2010 Jun;24(6):1151-64.
8 L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis. FASEB J. 2018 Mar;32(3):1364-1374. doi: 10.1096/fj.201700970. Epub 2018 Jan 3.
9 Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II. Bioorg Med Chem. 2018 Aug 7;26(14):4014-4024. doi: 10.1016/j.bmc.2018.06.027. Epub 2018 Jun 20.
10 Cytochrome P450 Mediated Bioactivation of Saracatinib. Chem Res Toxicol. 2016 Nov 21;29(11):1835-1842. doi: 10.1021/acs.chemrestox.6b00242. Epub 2016 Nov 3.
11 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
12 In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010 Oct;38(10):1688-97.